$ARQT

2 stories mentioning ARQTUpdated 10m ago

Every FINWIRES story that references ARQT, newest first.

Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis

Arcutis Biotherapeutics' (ARQT) Arcutis Canada unit said Thursday that Health Canada has approved Zoryve cream 0.05% to treat mild to moderate atopic dermatitis in children 2 to 5 years old.The approval is based on data from a phase 3 trial, which met its primary and key secondary endpoints, showing improvements in disease severity, with benefits observed as early as week 1, the company said.Trial results were well-tolerated through week 56, with treatment-emergent adverse events predominantly mild to moderate in severity, the company said.Price: $24.99, Change: $-1.47, Percent Change: -5.56%

$ARQT

Sectors51d ago

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

Healthcare stocks were edging higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Pacira Biosciences (PCRX) has agreed to sell its Iovera cold-therapy pain relief system to Zimmer Biomet (ZBH) for up to $140 million. Pacira BioSciences shares were up more than 3% and Zimmer Biomet stock declined by more than 1% pre-bell.Arcutis Biotherapeutics (ARQT) shares were up more than 1% after the company said the US Food and Drug Administration cleared an expanded use of its Zoryve cream to treat plaque psoriasis in children as young as 2 years old.Evotec (EVO) has expanded its Just-Evotec Biologics services with J.TRAIN, a new offering that lets biopharmaceutical companies use Evotec's manufacturing technology within their own facilities on a turnkey basis, the company said. Evotec shares were up more than 1% pre-bell.

$ARQT$EVO$IBB$PCRX$XLV$ZBH

Track with the FINWIRES app suite

FolioX

Track ARQT in your portfolio

WheelAI

Analyze ARQT options with the wheel strategy

StockInsider

See market sentiment on ARQT